Counterpoint Mutual Funds LLC Purchases New Position in Ralliant Corporation $RAL

Counterpoint Mutual Funds LLC purchased a new position in Ralliant Corporation (NYSE:RAL) in the first quarter, HoldingsChannel reports. The fund purchased 20,547 shares of the company’s stock, valued at approximately $855,000.

Several other institutional investors and hedge funds have also bought and sold shares of RAL. Allworth Financial LP increased its stake in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after acquiring an additional 293 shares in the last quarter. Rothschild Investment LLC lifted its position in Ralliant by 98.1% during the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after acquiring an additional 303 shares during the period. Keybank National Association OH boosted its stake in Ralliant by 1.6% during the fourth quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock worth $1,001,000 after acquiring an additional 305 shares in the last quarter. UMB Bank n.a. boosted its stake in Ralliant by 49.6% during the fourth quarter. UMB Bank n.a. now owns 983 shares of the company’s stock worth $50,000 after acquiring an additional 326 shares in the last quarter. Finally, Maryland State Retirement & Pension System grew its holdings in Ralliant by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock worth $1,117,000 after purchasing an additional 329 shares during the period.

Ralliant Stock Performance

RAL stock opened at $68.34 on Friday. The stock has a market capitalization of $7.65 billion and a PE ratio of -6.25. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $75.41. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The stock’s 50 day simple moving average is $60.61 and its 200 day simple moving average is $51.93.

Ralliant (NYSE:RAL) last posted its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business had revenue of $534.60 million during the quarter. Ralliant’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, research analysts forecast that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Truist Financial reaffirmed a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. Vertical Research downgraded Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price target on the stock. in a research note on Wednesday, May 27th. Wall Street Zen lowered Ralliant from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. Royal Bank Of Canada lifted their price objective on Ralliant from $47.00 to $64.00 and gave the company a “sector perform” rating in a research note on Wednesday, May 13th. Finally, Citigroup boosted their target price on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $69.00.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.